# peptides.cx — evidence and vendor-transparency index > peptides.cx publishes evidence-scored peptide monographs, safety and regulatory context, > sources, and clearly separated vendor information in 15 server-rendered languages. > Content is educational, not individualized medical advice, prescribing, dosing or emergency guidance. ## Editorial rules - Scientific and safety ratings are independent from vendor and affiliate relationships. - Missing prices, availability, laboratory data, sources, and reviewers are shown as missing, never inferred. - Vendor links can be sponsored and are visibly disclosed on the corresponding page. - Unapproved or investigational status is reported without implying that purchase or use is lawful in every country. - Full methodology: https://peptides.cx/editorial-policy and https://peptides.cx/methodology/evidence-grading ## Peptide monographs (59) ## BPC-157 Name: BPC-157 Canonical URL: https://peptides.cx/library/bpc-157 Localized URLs: en: https://peptides.cx/library/bpc-157; de: https://peptides.cx/de/library/bpc-157; fr: https://peptides.cx/fr/library/bpc-157; it: https://peptides.cx/it/library/bpc-157; es: https://peptides.cx/es/library/bpc-157; el: https://peptides.cx/el/library/bpc-157; pl: https://peptides.cx/pl/library/bpc-157; nl: https://peptides.cx/nl/library/bpc-157; cs: https://peptides.cx/cs/library/bpc-157; ro: https://peptides.cx/ro/library/bpc-157; bg: https://peptides.cx/bg/library/bpc-157; fi: https://peptides.cx/fi/library/bpc-157; sv: https://peptides.cx/sv/library/bpc-157; sk: https://peptides.cx/sk/library/bpc-157; lt: https://peptides.cx/lt/library/bpc-157 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Peer-reviewed human clinical trials are essentially absent. Claims about human recovery are extrapolated from animal work and personal reports. Preclinical evidence: A body of rodent studies reports accelerated healing of tendon, muscle, and gut tissue. These results have not been replicated in controlled human trials. Safety summary: Human safety data is lacking. Purity, sterility, and dosing of research-grade material are unverified. This is not a substitute for professional medical care. Regulatory context: Not an approved medicine in the EU/US. Sold as a research chemical only; not authorised for human use. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12195719/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## TB-500 / Thymosin Beta-4 Name: TB-500 / Thymosin Beta-4 Canonical URL: https://peptides.cx/library/tb-500 Localized URLs: en: https://peptides.cx/library/tb-500; de: https://peptides.cx/de/library/tb-500; fr: https://peptides.cx/fr/library/tb-500; it: https://peptides.cx/it/library/tb-500; es: https://peptides.cx/es/library/tb-500; el: https://peptides.cx/el/library/tb-500; pl: https://peptides.cx/pl/library/tb-500; nl: https://peptides.cx/nl/library/tb-500; cs: https://peptides.cx/cs/library/tb-500; ro: https://peptides.cx/ro/library/tb-500; bg: https://peptides.cx/bg/library/tb-500; fi: https://peptides.cx/fi/library/tb-500; sv: https://peptides.cx/sv/library/tb-500; sk: https://peptides.cx/sk/library/tb-500; lt: https://peptides.cx/lt/library/tb-500 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited. Thymosin Beta-4 itself has been studied in some clinical contexts, but the research-market 'TB-500' fragment lacks robust human trials. Preclinical evidence: Animal studies suggest roles in wound healing and cardiac tissue repair. Safety summary: Human safety data is limited. Material sold on the research market is not quality-assured for human use. Regulatory context: Not an approved medicine for general human use. Research chemical status in most jurisdictions. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.mdpi.com/2076-3417/16/12/6202 Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## GHK-Cu Name: GHK-Cu Canonical URL: https://peptides.cx/library/ghk-cu Localized URLs: en: https://peptides.cx/library/ghk-cu; de: https://peptides.cx/de/library/ghk-cu; fr: https://peptides.cx/fr/library/ghk-cu; it: https://peptides.cx/it/library/ghk-cu; es: https://peptides.cx/es/library/ghk-cu; el: https://peptides.cx/el/library/ghk-cu; pl: https://peptides.cx/pl/library/ghk-cu; nl: https://peptides.cx/nl/library/ghk-cu; cs: https://peptides.cx/cs/library/ghk-cu; ro: https://peptides.cx/ro/library/ghk-cu; bg: https://peptides.cx/bg/library/ghk-cu; fi: https://peptides.cx/fi/library/ghk-cu; sv: https://peptides.cx/sv/library/ghk-cu; sk: https://peptides.cx/sk/library/ghk-cu; lt: https://peptides.cx/lt/library/ghk-cu Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Topical cosmetic studies report improvements in skin appearance. Evidence for injected/systemic use is limited. Preclinical evidence: Animal and in-vitro work supports wound-healing and skin-remodelling roles. Safety summary: Topical cosmetic use is generally well tolerated. Injected use is not a validated cosmetic route and carries different risks. Regulatory context: Widely used as a cosmetic ingredient in topical products. Cosmetic use is broadly permitted; injectable use is a separate matter. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## KPV Name: KPV Canonical URL: https://peptides.cx/library/kpv Localized URLs: en: https://peptides.cx/library/kpv; de: https://peptides.cx/de/library/kpv; fr: https://peptides.cx/fr/library/kpv; it: https://peptides.cx/it/library/kpv; es: https://peptides.cx/es/library/kpv; el: https://peptides.cx/el/library/kpv; pl: https://peptides.cx/pl/library/kpv; nl: https://peptides.cx/nl/library/kpv; cs: https://peptides.cx/cs/library/kpv; ro: https://peptides.cx/ro/library/kpv; bg: https://peptides.cx/bg/library/kpv; fi: https://peptides.cx/fi/library/kpv; sv: https://peptides.cx/sv/library/kpv; sk: https://peptides.cx/sk/library/kpv; lt: https://peptides.cx/lt/library/kpv Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Very limited human data. Preclinical evidence: Preclinical work suggests anti-inflammatory activity in models of colitis. Safety summary: Human safety data is limited; research-market purity is unverified. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/18092346/, https://pubmed.ncbi.nlm.nih.gov/21222263/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Semax Name: Semax Canonical URL: https://peptides.cx/library/semax Localized URLs: en: https://peptides.cx/library/semax; de: https://peptides.cx/de/library/semax; fr: https://peptides.cx/fr/library/semax; it: https://peptides.cx/it/library/semax; es: https://peptides.cx/es/library/semax; el: https://peptides.cx/el/library/semax; pl: https://peptides.cx/pl/library/semax; nl: https://peptides.cx/nl/library/semax; cs: https://peptides.cx/cs/library/semax; ro: https://peptides.cx/ro/library/semax; bg: https://peptides.cx/bg/library/semax; fi: https://peptides.cx/fi/library/semax; sv: https://peptides.cx/sv/library/semax; sk: https://peptides.cx/sk/library/semax; lt: https://peptides.cx/lt/library/semax Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some human studies exist in the countries where it is used clinically; broader independent replication is limited. Preclinical evidence: Preclinical work reports neuroprotective and cognitive effects. Safety summary: Where used clinically it is intranasal and prescribed; research-market use is unverified. Regulatory context: Approved/used as a medicine in some countries (e.g. Russia); not approved in the EU/US. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/16362768/, https://pmc.ncbi.nlm.nih.gov/articles/PMC7350263/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Selank Name: Selank Canonical URL: https://peptides.cx/library/selank Localized URLs: en: https://peptides.cx/library/selank; de: https://peptides.cx/de/library/selank; fr: https://peptides.cx/fr/library/selank; it: https://peptides.cx/it/library/selank; es: https://peptides.cx/es/library/selank; el: https://peptides.cx/el/library/selank; pl: https://peptides.cx/pl/library/selank; nl: https://peptides.cx/nl/library/selank; cs: https://peptides.cx/cs/library/selank; ro: https://peptides.cx/ro/library/selank; bg: https://peptides.cx/bg/library/selank; fi: https://peptides.cx/fi/library/selank; sv: https://peptides.cx/sv/library/selank; sk: https://peptides.cx/sk/library/selank; lt: https://peptides.cx/lt/library/selank Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some regional clinical use; limited independent replication. Preclinical evidence: Preclinical anxiolytic effects reported. Safety summary: Research-market purity is unverified; not a validated treatment outside its regional approvals. Regulatory context: Used as a medicine in some countries; not approved in the EU/US. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/25176261/, https://pubmed.ncbi.nlm.nih.gov/28280289/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Epitalon Name: Epitalon Canonical URL: https://peptides.cx/library/epitalon Localized URLs: en: https://peptides.cx/library/epitalon; de: https://peptides.cx/de/library/epitalon; fr: https://peptides.cx/fr/library/epitalon; it: https://peptides.cx/it/library/epitalon; es: https://peptides.cx/es/library/epitalon; el: https://peptides.cx/el/library/epitalon; pl: https://peptides.cx/pl/library/epitalon; nl: https://peptides.cx/nl/library/epitalon; cs: https://peptides.cx/cs/library/epitalon; ro: https://peptides.cx/ro/library/epitalon; bg: https://peptides.cx/bg/library/epitalon; fi: https://peptides.cx/fi/library/epitalon; sv: https://peptides.cx/sv/library/epitalon; sk: https://peptides.cx/sk/library/epitalon; lt: https://peptides.cx/lt/library/epitalon Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Sparse and largely from a small number of research groups; independent replication is limited. Preclinical evidence: Some rodent longevity data reported by originating groups. Safety summary: Human safety data is weak. Claims should be treated with caution. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## MOTS-c Name: MOTS-c Canonical URL: https://peptides.cx/library/mots-c Localized URLs: en: https://peptides.cx/library/mots-c; de: https://peptides.cx/de/library/mots-c; fr: https://peptides.cx/fr/library/mots-c; it: https://peptides.cx/it/library/mots-c; es: https://peptides.cx/es/library/mots-c; el: https://peptides.cx/el/library/mots-c; pl: https://peptides.cx/pl/library/mots-c; nl: https://peptides.cx/nl/library/mots-c; cs: https://peptides.cx/cs/library/mots-c; ro: https://peptides.cx/ro/library/mots-c; bg: https://peptides.cx/bg/library/mots-c; fi: https://peptides.cx/fi/library/mots-c; sv: https://peptides.cx/sv/library/mots-c; sk: https://peptides.cx/sk/library/mots-c; lt: https://peptides.cx/lt/library/mots-c Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited; mostly observational and mechanistic. Preclinical evidence: Rodent studies report effects on insulin sensitivity and metabolism. Safety summary: Human safety data is limited; research-market material is unverified. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/, https://pubmed.ncbi.nlm.nih.gov/27216708/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## DSIP Name: DSIP Canonical URL: https://peptides.cx/library/dsip Localized URLs: en: https://peptides.cx/library/dsip; de: https://peptides.cx/de/library/dsip; fr: https://peptides.cx/fr/library/dsip; it: https://peptides.cx/it/library/dsip; es: https://peptides.cx/es/library/dsip; el: https://peptides.cx/el/library/dsip; pl: https://peptides.cx/pl/library/dsip; nl: https://peptides.cx/nl/library/dsip; cs: https://peptides.cx/cs/library/dsip; ro: https://peptides.cx/ro/library/dsip; bg: https://peptides.cx/bg/library/dsip; fi: https://peptides.cx/fi/library/dsip; sv: https://peptides.cx/sv/library/dsip; sk: https://peptides.cx/sk/library/dsip; lt: https://peptides.cx/lt/library/dsip Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Older human studies exist with mixed and inconsistent results. Preclinical evidence: Mixed preclinical findings. Safety summary: Human safety data is limited and dated. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/16539679/, https://pubmed.ncbi.nlm.nih.gov/3583493/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Ipamorelin Name: Ipamorelin Canonical URL: https://peptides.cx/library/ipamorelin Localized URLs: en: https://peptides.cx/library/ipamorelin; de: https://peptides.cx/de/library/ipamorelin; fr: https://peptides.cx/fr/library/ipamorelin; it: https://peptides.cx/it/library/ipamorelin; es: https://peptides.cx/es/library/ipamorelin; el: https://peptides.cx/el/library/ipamorelin; pl: https://peptides.cx/pl/library/ipamorelin; nl: https://peptides.cx/nl/library/ipamorelin; cs: https://peptides.cx/cs/library/ipamorelin; ro: https://peptides.cx/ro/library/ipamorelin; bg: https://peptides.cx/bg/library/ipamorelin; fi: https://peptides.cx/fi/library/ipamorelin; sv: https://peptides.cx/sv/library/ipamorelin; sk: https://peptides.cx/sk/library/ipamorelin; lt: https://peptides.cx/lt/library/ipamorelin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some early clinical study history; not an approved therapy. Preclinical evidence: Preclinical GH-release effects documented. Safety summary: Hormonal effects carry real risks; not a validated therapy. Professional supervision matters for anything hormonal. Regulatory context: Not an approved medicine for general use. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9 Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## CJC-1295 Name: CJC-1295 Canonical URL: https://peptides.cx/library/cjc-1295 Localized URLs: en: https://peptides.cx/library/cjc-1295; de: https://peptides.cx/de/library/cjc-1295; fr: https://peptides.cx/fr/library/cjc-1295; it: https://peptides.cx/it/library/cjc-1295; es: https://peptides.cx/es/library/cjc-1295; el: https://peptides.cx/el/library/cjc-1295; pl: https://peptides.cx/pl/library/cjc-1295; nl: https://peptides.cx/nl/library/cjc-1295; cs: https://peptides.cx/cs/library/cjc-1295; ro: https://peptides.cx/ro/library/cjc-1295; bg: https://peptides.cx/bg/library/cjc-1295; fi: https://peptides.cx/fi/library/cjc-1295; sv: https://peptides.cx/sv/library/cjc-1295; sk: https://peptides.cx/sk/library/cjc-1295; lt: https://peptides.cx/lt/library/cjc-1295 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited early clinical history; not an approved therapy. Preclinical evidence: Preclinical GH-axis effects documented. Safety summary: Hormonal effects carry real risks; not a validated therapy. Regulatory context: Not an approved medicine for general use. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/16352683/, https://pubmed.ncbi.nlm.nih.gov/17018654/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## AOD-9604 Name: AOD-9604 Canonical URL: https://peptides.cx/library/aod-9604 Localized URLs: en: https://peptides.cx/library/aod-9604; de: https://peptides.cx/de/library/aod-9604; fr: https://peptides.cx/fr/library/aod-9604; it: https://peptides.cx/it/library/aod-9604; es: https://peptides.cx/es/library/aod-9604; el: https://peptides.cx/el/library/aod-9604; pl: https://peptides.cx/pl/library/aod-9604; nl: https://peptides.cx/nl/library/aod-9604; cs: https://peptides.cx/cs/library/aod-9604; ro: https://peptides.cx/ro/library/aod-9604; bg: https://peptides.cx/bg/library/aod-9604; fi: https://peptides.cx/fi/library/aod-9604; sv: https://peptides.cx/sv/library/aod-9604; sk: https://peptides.cx/sk/library/aod-9604; lt: https://peptides.cx/lt/library/aod-9604 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Clinical trials for obesity did not demonstrate sufficient efficacy for approval. Preclinical evidence: Some preclinical lipolytic effects reported. Safety summary: Not an approved therapy; efficacy for fat loss is not established. Regulatory context: Not an approved weight-loss medicine; clinical development did not lead to approval. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/11146367/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Melanotan I Name: Melanotan I Canonical URL: https://peptides.cx/library/melanotan-1 Localized URLs: en: https://peptides.cx/library/melanotan-1; de: https://peptides.cx/de/library/melanotan-1; fr: https://peptides.cx/fr/library/melanotan-1; it: https://peptides.cx/it/library/melanotan-1; es: https://peptides.cx/es/library/melanotan-1; el: https://peptides.cx/el/library/melanotan-1; pl: https://peptides.cx/pl/library/melanotan-1; nl: https://peptides.cx/nl/library/melanotan-1; cs: https://peptides.cx/cs/library/melanotan-1; ro: https://peptides.cx/ro/library/melanotan-1; bg: https://peptides.cx/bg/library/melanotan-1; fi: https://peptides.cx/fi/library/melanotan-1; sv: https://peptides.cx/sv/library/melanotan-1; sk: https://peptides.cx/sk/library/melanotan-1; lt: https://peptides.cx/lt/library/melanotan-1 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: The related approved drug has clinical evidence for a specific rare condition; general research-market use does not. Preclinical evidence: Melanocortin effects well characterised preclinically. Safety summary: Unregulated research-market use carries risks including effects on existing moles; dermatological monitoring matters. Regulatory context: A related compound (afamelanotide) is an approved medicine for a rare condition; research-market Melanotan I is not. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48 Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Melanotan II Name: Melanotan II Canonical URL: https://peptides.cx/library/melanotan-2 Localized URLs: en: https://peptides.cx/library/melanotan-2; de: https://peptides.cx/de/library/melanotan-2; fr: https://peptides.cx/fr/library/melanotan-2; it: https://peptides.cx/it/library/melanotan-2; es: https://peptides.cx/es/library/melanotan-2; el: https://peptides.cx/el/library/melanotan-2; pl: https://peptides.cx/pl/library/melanotan-2; nl: https://peptides.cx/nl/library/melanotan-2; cs: https://peptides.cx/cs/library/melanotan-2; ro: https://peptides.cx/ro/library/melanotan-2; bg: https://peptides.cx/bg/library/melanotan-2; fi: https://peptides.cx/fi/library/melanotan-2; sv: https://peptides.cx/sv/library/melanotan-2; sk: https://peptides.cx/sk/library/melanotan-2; lt: https://peptides.cx/lt/library/melanotan-2 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: No approval; multiple regulator safety warnings exist. Preclinical evidence: Melanocortin effects characterised preclinically. Safety summary: Regulators have issued safety warnings. Effects on moles, blood pressure, and other systems are of concern. Regulatory context: Not an approved medicine. Sale for human use is restricted in many countries. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/40210573/, https://pubmed.ncbi.nlm.nih.gov/23121206/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Thymosin Alpha-1 Name: Thymosin Alpha-1 Canonical URL: https://peptides.cx/library/thymosin-alpha-1 Localized URLs: en: https://peptides.cx/library/thymosin-alpha-1; de: https://peptides.cx/de/library/thymosin-alpha-1; fr: https://peptides.cx/fr/library/thymosin-alpha-1; it: https://peptides.cx/it/library/thymosin-alpha-1; es: https://peptides.cx/es/library/thymosin-alpha-1; el: https://peptides.cx/el/library/thymosin-alpha-1; pl: https://peptides.cx/pl/library/thymosin-alpha-1; nl: https://peptides.cx/nl/library/thymosin-alpha-1; cs: https://peptides.cx/cs/library/thymosin-alpha-1; ro: https://peptides.cx/ro/library/thymosin-alpha-1; bg: https://peptides.cx/bg/library/thymosin-alpha-1; fi: https://peptides.cx/fi/library/thymosin-alpha-1; sv: https://peptides.cx/sv/library/thymosin-alpha-1; sk: https://peptides.cx/sk/library/thymosin-alpha-1; lt: https://peptides.cx/lt/library/thymosin-alpha-1 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Clinical evidence exists for specific approved indications in the countries where it is registered. Preclinical evidence: Immune-modulating effects documented preclinically. Safety summary: Where approved it is prescribed and monitored; research-market use is unverified. Regulatory context: Approved as a medicine (thymalfasin) in some countries for specific indications; not universally approved. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6742685/, https://pubmed.ncbi.nlm.nih.gov/15992078/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## LL-37 Name: LL-37 Canonical URL: https://peptides.cx/library/ll-37 Localized URLs: en: https://peptides.cx/library/ll-37; de: https://peptides.cx/de/library/ll-37; fr: https://peptides.cx/fr/library/ll-37; it: https://peptides.cx/it/library/ll-37; es: https://peptides.cx/es/library/ll-37; el: https://peptides.cx/el/library/ll-37; pl: https://peptides.cx/pl/library/ll-37; nl: https://peptides.cx/nl/library/ll-37; cs: https://peptides.cx/cs/library/ll-37; ro: https://peptides.cx/ro/library/ll-37; bg: https://peptides.cx/bg/library/ll-37; fi: https://peptides.cx/fi/library/ll-37; sv: https://peptides.cx/sv/library/ll-37; sk: https://peptides.cx/sk/library/ll-37; lt: https://peptides.cx/lt/library/ll-37 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited; largely mechanistic and preclinical. Preclinical evidence: Antimicrobial and immune effects reported. Safety summary: Human safety data is limited; research-market material is unverified. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/16716248/, https://pmc.ncbi.nlm.nih.gov/articles/PMC4034075/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Kisspeptin-10 Name: Kisspeptin-10 Canonical URL: https://peptides.cx/library/kisspeptin-10 Localized URLs: en: https://peptides.cx/library/kisspeptin-10; de: https://peptides.cx/de/library/kisspeptin-10; fr: https://peptides.cx/fr/library/kisspeptin-10; it: https://peptides.cx/it/library/kisspeptin-10; es: https://peptides.cx/es/library/kisspeptin-10; el: https://peptides.cx/el/library/kisspeptin-10; pl: https://peptides.cx/pl/library/kisspeptin-10; nl: https://peptides.cx/nl/library/kisspeptin-10; cs: https://peptides.cx/cs/library/kisspeptin-10; ro: https://peptides.cx/ro/library/kisspeptin-10; bg: https://peptides.cx/bg/library/kisspeptin-10; fi: https://peptides.cx/fi/library/kisspeptin-10; sv: https://peptides.cx/sv/library/kisspeptin-10; sk: https://peptides.cx/sk/library/kisspeptin-10; lt: https://peptides.cx/lt/library/kisspeptin-10 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Studied in controlled clinical research on reproductive endocrinology. Preclinical evidence: Well-characterised roles in reproductive physiology. Safety summary: Affects the reproductive hormone axis; only appropriate under clinical/research supervision. Regulatory context: Investigational; used in some clinical research settings. Not a general-use medicine. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC3380939/, https://pmc.ncbi.nlm.nih.gov/articles/PMC4063702/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## GHRP-2 Name: GHRP-2 Canonical URL: https://peptides.cx/library/ghrp-2 Localized URLs: en: https://peptides.cx/library/ghrp-2; de: https://peptides.cx/de/library/ghrp-2; fr: https://peptides.cx/fr/library/ghrp-2; it: https://peptides.cx/it/library/ghrp-2; es: https://peptides.cx/es/library/ghrp-2; el: https://peptides.cx/el/library/ghrp-2; pl: https://peptides.cx/pl/library/ghrp-2; nl: https://peptides.cx/nl/library/ghrp-2; cs: https://peptides.cx/cs/library/ghrp-2; ro: https://peptides.cx/ro/library/ghrp-2; bg: https://peptides.cx/bg/library/ghrp-2; fi: https://peptides.cx/fi/library/ghrp-2; sv: https://peptides.cx/sv/library/ghrp-2; sk: https://peptides.cx/sk/library/ghrp-2; lt: https://peptides.cx/lt/library/ghrp-2 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some pharmacological study history; not an approved therapy. Preclinical evidence: Preclinical GH-release effects documented. Safety summary: Hormonal effects carry real risks; not a validated therapy. Regulatory context: Not an approved medicine for general use. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/17609397/, https://pubmed.ncbi.nlm.nih.gov/15230633/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## GHRP-6 Name: GHRP-6 Canonical URL: https://peptides.cx/library/ghrp-6 Localized URLs: en: https://peptides.cx/library/ghrp-6; de: https://peptides.cx/de/library/ghrp-6; fr: https://peptides.cx/fr/library/ghrp-6; it: https://peptides.cx/it/library/ghrp-6; es: https://peptides.cx/es/library/ghrp-6; el: https://peptides.cx/el/library/ghrp-6; pl: https://peptides.cx/pl/library/ghrp-6; nl: https://peptides.cx/nl/library/ghrp-6; cs: https://peptides.cx/cs/library/ghrp-6; ro: https://peptides.cx/ro/library/ghrp-6; bg: https://peptides.cx/bg/library/ghrp-6; fi: https://peptides.cx/fi/library/ghrp-6; sv: https://peptides.cx/sv/library/ghrp-6; sk: https://peptides.cx/sk/library/ghrp-6; lt: https://peptides.cx/lt/library/ghrp-6 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some pharmacological study history; not an approved therapy. Preclinical evidence: Preclinical GH-release and appetite effects documented. Safety summary: Hormonal effects carry real risks; not a validated therapy. Regulatory context: Not an approved medicine for general use. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/7617137/, https://pubmed.ncbi.nlm.nih.gov/9543138/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Semaglutide Name: Semaglutide Canonical URL: https://peptides.cx/library/semaglutide Localized URLs: en: https://peptides.cx/library/semaglutide; de: https://peptides.cx/de/library/semaglutide; fr: https://peptides.cx/fr/library/semaglutide; it: https://peptides.cx/it/library/semaglutide; es: https://peptides.cx/es/library/semaglutide; el: https://peptides.cx/el/library/semaglutide; pl: https://peptides.cx/pl/library/semaglutide; nl: https://peptides.cx/nl/library/semaglutide; cs: https://peptides.cx/cs/library/semaglutide; ro: https://peptides.cx/ro/library/semaglutide; bg: https://peptides.cx/bg/library/semaglutide; fi: https://peptides.cx/fi/library/semaglutide; sv: https://peptides.cx/sv/library/semaglutide; sk: https://peptides.cx/sk/library/semaglutide; lt: https://peptides.cx/lt/library/semaglutide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Preclinical evidence: Extensively characterised in preclinical models. Safety summary: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Regulatory context: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Tirzepatide Name: Tirzepatide Canonical URL: https://peptides.cx/library/tirzepatide Localized URLs: en: https://peptides.cx/library/tirzepatide; de: https://peptides.cx/de/library/tirzepatide; fr: https://peptides.cx/fr/library/tirzepatide; it: https://peptides.cx/it/library/tirzepatide; es: https://peptides.cx/es/library/tirzepatide; el: https://peptides.cx/el/library/tirzepatide; pl: https://peptides.cx/pl/library/tirzepatide; nl: https://peptides.cx/nl/library/tirzepatide; cs: https://peptides.cx/cs/library/tirzepatide; ro: https://peptides.cx/ro/library/tirzepatide; bg: https://peptides.cx/bg/library/tirzepatide; fi: https://peptides.cx/fi/library/tirzepatide; sv: https://peptides.cx/sv/library/tirzepatide; sk: https://peptides.cx/sk/library/tirzepatide; lt: https://peptides.cx/lt/library/tirzepatide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Preclinical evidence: Extensively characterised in preclinical models. Safety summary: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Regulatory context: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Retatrutide Name: Retatrutide Canonical URL: https://peptides.cx/library/retatrutide Localized URLs: en: https://peptides.cx/library/retatrutide; de: https://peptides.cx/de/library/retatrutide; fr: https://peptides.cx/fr/library/retatrutide; it: https://peptides.cx/it/library/retatrutide; es: https://peptides.cx/es/library/retatrutide; el: https://peptides.cx/el/library/retatrutide; pl: https://peptides.cx/pl/library/retatrutide; nl: https://peptides.cx/nl/library/retatrutide; cs: https://peptides.cx/cs/library/retatrutide; ro: https://peptides.cx/ro/library/retatrutide; bg: https://peptides.cx/bg/library/retatrutide; fi: https://peptides.cx/fi/library/retatrutide; sv: https://peptides.cx/sv/library/retatrutide; sk: https://peptides.cx/sk/library/retatrutide; lt: https://peptides.cx/lt/library/retatrutide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Phase 2 trials report substantial weight loss; phase 3 evaluation ongoing. Not yet approved. Preclinical evidence: Characterised in preclinical metabolic models. Safety summary: An investigational compound with no regulatory approval anywhere, so no authority has assessed its risk-benefit profile and no approved prescribing information exists. Long-term safety in humans is unknown, and research-market material is not quality-assured. Regulatory context: Investigational — not an approved medicine. Under clinical evaluation; not for unsupervised research-market use. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/37366315/, https://pubmed.ncbi.nlm.nih.gov/37385280/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Liraglutide Name: Liraglutide Canonical URL: https://peptides.cx/library/liraglutide Localized URLs: en: https://peptides.cx/library/liraglutide; de: https://peptides.cx/de/library/liraglutide; fr: https://peptides.cx/fr/library/liraglutide; it: https://peptides.cx/it/library/liraglutide; es: https://peptides.cx/es/library/liraglutide; el: https://peptides.cx/el/library/liraglutide; pl: https://peptides.cx/pl/library/liraglutide; nl: https://peptides.cx/nl/library/liraglutide; cs: https://peptides.cx/cs/library/liraglutide; ro: https://peptides.cx/ro/library/liraglutide; bg: https://peptides.cx/bg/library/liraglutide; fi: https://peptides.cx/fi/library/liraglutide; sv: https://peptides.cx/sv/library/liraglutide; sk: https://peptides.cx/sk/library/liraglutide; lt: https://peptides.cx/lt/library/liraglutide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Strong clinical trial evidence and regulatory approval for glycemic control and weight loss. Preclinical evidence: Extensively characterised in preclinical models. Safety summary: A prescription medicine that must be used under medical supervision, with a prescribing information document that lists its risks in full. Research-market material is not the licensed product: it is not quality-assured, not dispensed by a pharmacist, and carries no prescribing information. Obtaining or using it without a prescription is unlawful in many countries. Regulatory context: Approved prescription medicine for type 2 diabetes and weight management. Prescription-only; not for unsupervised research-market use. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/26132939/, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Tesamorelin Name: Tesamorelin Canonical URL: https://peptides.cx/library/tesamorelin Localized URLs: en: https://peptides.cx/library/tesamorelin; de: https://peptides.cx/de/library/tesamorelin; fr: https://peptides.cx/fr/library/tesamorelin; it: https://peptides.cx/it/library/tesamorelin; es: https://peptides.cx/es/library/tesamorelin; el: https://peptides.cx/el/library/tesamorelin; pl: https://peptides.cx/pl/library/tesamorelin; nl: https://peptides.cx/nl/library/tesamorelin; cs: https://peptides.cx/cs/library/tesamorelin; ro: https://peptides.cx/ro/library/tesamorelin; bg: https://peptides.cx/bg/library/tesamorelin; fi: https://peptides.cx/fi/library/tesamorelin; sv: https://peptides.cx/sv/library/tesamorelin; sk: https://peptides.cx/sk/library/tesamorelin; lt: https://peptides.cx/lt/library/tesamorelin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Clinical evidence supports its approved indication; other uses are not established. Preclinical evidence: GH-axis effects characterised preclinically. Safety summary: A prescription medicine with real hormonal effects; must be used under medical supervision. Not for unsupervised use. Regulatory context: Approved as a prescription medicine (Egrifta) for HIV-associated lipodystrophy in some jurisdictions; prescription-only. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Sermorelin Name: Sermorelin Canonical URL: https://peptides.cx/library/sermorelin Localized URLs: en: https://peptides.cx/library/sermorelin; de: https://peptides.cx/de/library/sermorelin; fr: https://peptides.cx/fr/library/sermorelin; it: https://peptides.cx/it/library/sermorelin; es: https://peptides.cx/es/library/sermorelin; el: https://peptides.cx/el/library/sermorelin; pl: https://peptides.cx/pl/library/sermorelin; nl: https://peptides.cx/nl/library/sermorelin; cs: https://peptides.cx/cs/library/sermorelin; ro: https://peptides.cx/ro/library/sermorelin; bg: https://peptides.cx/bg/library/sermorelin; fi: https://peptides.cx/fi/library/sermorelin; sv: https://peptides.cx/sv/library/sermorelin; sk: https://peptides.cx/sk/library/sermorelin; lt: https://peptides.cx/lt/library/sermorelin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Some historical clinical use; modern research-market use is not a validated therapy. Preclinical evidence: GH-release effects documented. Safety summary: Hormonal effects carry real risks; supervision matters for anything affecting the GH axis. Regulatory context: Previously marketed as a medicine for diagnostic/therapeutic use; availability and status vary by country. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/8329830/, https://pubmed.ncbi.nlm.nih.gov/8329825/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Hexarelin Name: Hexarelin Canonical URL: https://peptides.cx/library/hexarelin Localized URLs: en: https://peptides.cx/library/hexarelin; de: https://peptides.cx/de/library/hexarelin; fr: https://peptides.cx/fr/library/hexarelin; it: https://peptides.cx/it/library/hexarelin; es: https://peptides.cx/es/library/hexarelin; el: https://peptides.cx/el/library/hexarelin; pl: https://peptides.cx/pl/library/hexarelin; nl: https://peptides.cx/nl/library/hexarelin; cs: https://peptides.cx/cs/library/hexarelin; ro: https://peptides.cx/ro/library/hexarelin; bg: https://peptides.cx/bg/library/hexarelin; fi: https://peptides.cx/fi/library/hexarelin; sv: https://peptides.cx/sv/library/hexarelin; sk: https://peptides.cx/sk/library/hexarelin; lt: https://peptides.cx/lt/library/hexarelin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited pharmacological study history; not an approved therapy. Preclinical evidence: GH-release and cardiovascular effects reported preclinically. Safety summary: Hormonal effects and potential desensitisation; not a validated therapy. Regulatory context: Not an approved medicine for general use. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/10342360/, https://pubmed.ncbi.nlm.nih.gov/25278975/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## MGF / PEG-MGF Name: MGF / PEG-MGF Canonical URL: https://peptides.cx/library/mgf Localized URLs: en: https://peptides.cx/library/mgf; de: https://peptides.cx/de/library/mgf; fr: https://peptides.cx/fr/library/mgf; it: https://peptides.cx/it/library/mgf; es: https://peptides.cx/es/library/mgf; el: https://peptides.cx/el/library/mgf; pl: https://peptides.cx/pl/library/mgf; nl: https://peptides.cx/nl/library/mgf; cs: https://peptides.cx/cs/library/mgf; ro: https://peptides.cx/ro/library/mgf; bg: https://peptides.cx/bg/library/mgf; fi: https://peptides.cx/fi/library/mgf; sv: https://peptides.cx/sv/library/mgf; sk: https://peptides.cx/sk/library/mgf; lt: https://peptides.cx/lt/library/mgf Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Minimal; largely mechanistic and anecdotal. Preclinical evidence: Some muscle-repair signalling reported. Safety summary: Growth-factor signalling carries theoretical risks; unverified research-market material. Regulatory context: Not an approved medicine. Research chemical status; prohibited in sport. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/20130113/, https://pmc.ncbi.nlm.nih.gov/articles/PMC3795771/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## IGF-1 LR3 Name: IGF-1 LR3 Canonical URL: https://peptides.cx/library/igf-1-lr3 Localized URLs: en: https://peptides.cx/library/igf-1-lr3; de: https://peptides.cx/de/library/igf-1-lr3; fr: https://peptides.cx/fr/library/igf-1-lr3; it: https://peptides.cx/it/library/igf-1-lr3; es: https://peptides.cx/es/library/igf-1-lr3; el: https://peptides.cx/el/library/igf-1-lr3; pl: https://peptides.cx/pl/library/igf-1-lr3; nl: https://peptides.cx/nl/library/igf-1-lr3; cs: https://peptides.cx/cs/library/igf-1-lr3; ro: https://peptides.cx/ro/library/igf-1-lr3; bg: https://peptides.cx/bg/library/igf-1-lr3; fi: https://peptides.cx/fi/library/igf-1-lr3; sv: https://peptides.cx/sv/library/igf-1-lr3; sk: https://peptides.cx/sk/library/igf-1-lr3; lt: https://peptides.cx/lt/library/igf-1-lr3 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: No approval for the research-market form; safety data is lacking. Preclinical evidence: Growth and metabolic effects documented. Safety summary: Potent growth-factor with risks including hypoglycaemia and theoretical proliferative concerns. Not a validated therapy. Regulatory context: Not an approved medicine for general use; prohibited in sport. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/17172665/, https://pubmed.ncbi.nlm.nih.gov/33587816/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## PT-141 (Bremelanotide) Name: PT-141 (Bremelanotide) Canonical URL: https://peptides.cx/library/pt-141 Localized URLs: en: https://peptides.cx/library/pt-141; de: https://peptides.cx/de/library/pt-141; fr: https://peptides.cx/fr/library/pt-141; it: https://peptides.cx/it/library/pt-141; es: https://peptides.cx/es/library/pt-141; el: https://peptides.cx/el/library/pt-141; pl: https://peptides.cx/pl/library/pt-141; nl: https://peptides.cx/nl/library/pt-141; cs: https://peptides.cx/cs/library/pt-141; ro: https://peptides.cx/ro/library/pt-141; bg: https://peptides.cx/bg/library/pt-141; fi: https://peptides.cx/fi/library/pt-141; sv: https://peptides.cx/sv/library/pt-141; sk: https://peptides.cx/sk/library/pt-141; lt: https://peptides.cx/lt/library/pt-141 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Clinical evidence supports its approved indication. Preclinical evidence: Melanocortin effects characterised. Safety summary: Can affect blood pressure and cause nausea; prescription medicine that needs supervision. Regulatory context: Approved as a prescription medicine (Vyleesi) for a specific indication in some jurisdictions; prescription-only. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Follistatin Name: Follistatin Canonical URL: https://peptides.cx/library/follistatin Localized URLs: en: https://peptides.cx/library/follistatin; de: https://peptides.cx/de/library/follistatin; fr: https://peptides.cx/fr/library/follistatin; it: https://peptides.cx/it/library/follistatin; es: https://peptides.cx/es/library/follistatin; el: https://peptides.cx/el/library/follistatin; pl: https://peptides.cx/pl/library/follistatin; nl: https://peptides.cx/nl/library/follistatin; cs: https://peptides.cx/cs/library/follistatin; ro: https://peptides.cx/ro/library/follistatin; bg: https://peptides.cx/bg/library/follistatin; fi: https://peptides.cx/fi/library/follistatin; sv: https://peptides.cx/sv/library/follistatin; sk: https://peptides.cx/sk/library/follistatin; lt: https://peptides.cx/lt/library/follistatin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Largely experimental (gene-therapy research); research-market peptide use is unvalidated. Preclinical evidence: Muscle-growth effects in models. Safety summary: Manipulating the myostatin pathway has unknown long-term human risks; unverified material. Regulatory context: Not an approved medicine. Research/experimental status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/27858738/, https://pubmed.ncbi.nlm.nih.gov/20810712/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## SS-31 (Elamipretide) Name: SS-31 (Elamipretide) Canonical URL: https://peptides.cx/library/ss-31 Localized URLs: en: https://peptides.cx/library/ss-31; de: https://peptides.cx/de/library/ss-31; fr: https://peptides.cx/fr/library/ss-31; it: https://peptides.cx/it/library/ss-31; es: https://peptides.cx/es/library/ss-31; el: https://peptides.cx/el/library/ss-31; pl: https://peptides.cx/pl/library/ss-31; nl: https://peptides.cx/nl/library/ss-31; cs: https://peptides.cx/cs/library/ss-31; ro: https://peptides.cx/ro/library/ss-31; bg: https://peptides.cx/bg/library/ss-31; fi: https://peptides.cx/fi/library/ss-31; sv: https://peptides.cx/sv/library/ss-31; sk: https://peptides.cx/sk/library/ss-31; lt: https://peptides.cx/lt/library/ss-31 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Studied in controlled clinical trials with mixed results; not approved. Preclinical evidence: Protective mitochondrial effects reported. Safety summary: Investigational; research-market material is not the studied clinical product. Regulatory context: Investigational; studied in clinical trials. Not an approved general-use medicine. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7935714/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10382259/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Humanin Name: Humanin Canonical URL: https://peptides.cx/library/humanin Localized URLs: en: https://peptides.cx/library/humanin; de: https://peptides.cx/de/library/humanin; fr: https://peptides.cx/fr/library/humanin; it: https://peptides.cx/it/library/humanin; es: https://peptides.cx/es/library/humanin; el: https://peptides.cx/el/library/humanin; pl: https://peptides.cx/pl/library/humanin; nl: https://peptides.cx/nl/library/humanin; cs: https://peptides.cx/cs/library/humanin; ro: https://peptides.cx/ro/library/humanin; bg: https://peptides.cx/bg/library/humanin; fi: https://peptides.cx/fi/library/humanin; sv: https://peptides.cx/sv/library/humanin; sk: https://peptides.cx/sk/library/humanin; lt: https://peptides.cx/lt/library/humanin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited; largely observational and mechanistic. Preclinical evidence: Cytoprotective effects reported. Safety summary: Human safety data is limited; unverified research-market material. Regulatory context: Not an approved medicine. Research status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/30582721/, https://pubmed.ncbi.nlm.nih.gov/23402768/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Gonadorelin Name: Gonadorelin Canonical URL: https://peptides.cx/library/gonadorelin Localized URLs: en: https://peptides.cx/library/gonadorelin; de: https://peptides.cx/de/library/gonadorelin; fr: https://peptides.cx/fr/library/gonadorelin; it: https://peptides.cx/it/library/gonadorelin; es: https://peptides.cx/es/library/gonadorelin; el: https://peptides.cx/el/library/gonadorelin; pl: https://peptides.cx/pl/library/gonadorelin; nl: https://peptides.cx/nl/library/gonadorelin; cs: https://peptides.cx/cs/library/gonadorelin; ro: https://peptides.cx/ro/library/gonadorelin; bg: https://peptides.cx/bg/library/gonadorelin; fi: https://peptides.cx/fi/library/gonadorelin; sv: https://peptides.cx/sv/library/gonadorelin; sk: https://peptides.cx/sk/library/gonadorelin; lt: https://peptides.cx/lt/library/gonadorelin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Clinical evidence for approved endocrine uses. Preclinical evidence: Well characterised. Safety summary: Affects the reproductive hormone axis; appropriate only under medical supervision. Regulatory context: Approved as a medicine for specific endocrine indications in some jurisdictions; prescription-only. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10201297/, https://pubmed.ncbi.nlm.nih.gov/26365959/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Cerebrolysin Name: Cerebrolysin Canonical URL: https://peptides.cx/library/cerebrolysin Localized URLs: en: https://peptides.cx/library/cerebrolysin; de: https://peptides.cx/de/library/cerebrolysin; fr: https://peptides.cx/fr/library/cerebrolysin; it: https://peptides.cx/it/library/cerebrolysin; es: https://peptides.cx/es/library/cerebrolysin; el: https://peptides.cx/el/library/cerebrolysin; pl: https://peptides.cx/pl/library/cerebrolysin; nl: https://peptides.cx/nl/library/cerebrolysin; cs: https://peptides.cx/cs/library/cerebrolysin; ro: https://peptides.cx/ro/library/cerebrolysin; bg: https://peptides.cx/bg/library/cerebrolysin; fi: https://peptides.cx/fi/library/cerebrolysin; sv: https://peptides.cx/sv/library/cerebrolysin; sk: https://peptides.cx/sk/library/cerebrolysin; lt: https://peptides.cx/lt/library/cerebrolysin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Regional clinical use; independent evidence is mixed. Preclinical evidence: Neurotrophic effects reported. Safety summary: Where used it is prescribed and monitored; research-market material is unverified. Regulatory context: Used as a medicine in some countries; not approved in the US. Prescription where marketed. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/32662068/, https://pmc.ncbi.nlm.nih.gov/articles/PMC8708612/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## N-Acetyl Semax Amidate Name: N-Acetyl Semax Amidate Canonical URL: https://peptides.cx/library/n-acetyl-semax Localized URLs: en: https://peptides.cx/library/n-acetyl-semax; de: https://peptides.cx/de/library/n-acetyl-semax; fr: https://peptides.cx/fr/library/n-acetyl-semax; it: https://peptides.cx/it/library/n-acetyl-semax; es: https://peptides.cx/es/library/n-acetyl-semax; el: https://peptides.cx/el/library/n-acetyl-semax; pl: https://peptides.cx/pl/library/n-acetyl-semax; nl: https://peptides.cx/nl/library/n-acetyl-semax; cs: https://peptides.cx/cs/library/n-acetyl-semax; ro: https://peptides.cx/ro/library/n-acetyl-semax; bg: https://peptides.cx/bg/library/n-acetyl-semax; fi: https://peptides.cx/fi/library/n-acetyl-semax; sv: https://peptides.cx/sv/library/n-acetyl-semax; sk: https://peptides.cx/sk/library/n-acetyl-semax; lt: https://peptides.cx/lt/library/n-acetyl-semax Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited; extrapolated largely from Semax research. Preclinical evidence: Preclinical cognitive effects reported for the Semax family. Safety summary: Research-market purity is unverified; not a validated therapy. Regulatory context: Not approved in the EU/US; related to a medicine used in some countries. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: No suitable primary study or review specific to this entry was identified during the last editorial review. Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Dihexa Name: Dihexa Canonical URL: https://peptides.cx/library/dihexa Localized URLs: en: https://peptides.cx/library/dihexa; de: https://peptides.cx/de/library/dihexa; fr: https://peptides.cx/fr/library/dihexa; it: https://peptides.cx/it/library/dihexa; es: https://peptides.cx/es/library/dihexa; el: https://peptides.cx/el/library/dihexa; pl: https://peptides.cx/pl/library/dihexa; nl: https://peptides.cx/nl/library/dihexa; cs: https://peptides.cx/cs/library/dihexa; ro: https://peptides.cx/ro/library/dihexa; bg: https://peptides.cx/bg/library/dihexa; fi: https://peptides.cx/fi/library/dihexa; sv: https://peptides.cx/sv/library/dihexa; sk: https://peptides.cx/sk/library/dihexa; lt: https://peptides.cx/lt/library/dihexa Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Essentially none. Preclinical evidence: Preclinical cognitive effects reported. Safety summary: No human safety data; proliferative pathway involvement warrants caution. Regulatory context: Not an approved medicine. Research chemical status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/25187433/, https://pubmed.ncbi.nlm.nih.gov/34827486/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## FOXO4-DRI Name: FOXO4-DRI Canonical URL: https://peptides.cx/library/foxo4-dri Localized URLs: en: https://peptides.cx/library/foxo4-dri; de: https://peptides.cx/de/library/foxo4-dri; fr: https://peptides.cx/fr/library/foxo4-dri; it: https://peptides.cx/it/library/foxo4-dri; es: https://peptides.cx/es/library/foxo4-dri; el: https://peptides.cx/el/library/foxo4-dri; pl: https://peptides.cx/pl/library/foxo4-dri; nl: https://peptides.cx/nl/library/foxo4-dri; cs: https://peptides.cx/cs/library/foxo4-dri; ro: https://peptides.cx/ro/library/foxo4-dri; bg: https://peptides.cx/bg/library/foxo4-dri; fi: https://peptides.cx/fi/library/foxo4-dri; sv: https://peptides.cx/sv/library/foxo4-dri; sk: https://peptides.cx/sk/library/foxo4-dri; lt: https://peptides.cx/lt/library/foxo4-dri Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: None; preclinical only. Preclinical evidence: Some senolytic effects reported in mouse studies. Safety summary: Highly experimental with unknown human safety; unverified material. Regulatory context: Not an approved medicine. Experimental research compound. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/28340339/, https://pmc.ncbi.nlm.nih.gov/articles/PMC8116695/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Adipotide Name: Adipotide Canonical URL: https://peptides.cx/library/adipotide Localized URLs: en: https://peptides.cx/library/adipotide; de: https://peptides.cx/de/library/adipotide; fr: https://peptides.cx/fr/library/adipotide; it: https://peptides.cx/it/library/adipotide; es: https://peptides.cx/es/library/adipotide; el: https://peptides.cx/el/library/adipotide; pl: https://peptides.cx/pl/library/adipotide; nl: https://peptides.cx/nl/library/adipotide; cs: https://peptides.cx/cs/library/adipotide; ro: https://peptides.cx/ro/library/adipotide; bg: https://peptides.cx/bg/library/adipotide; fi: https://peptides.cx/fi/library/adipotide; sv: https://peptides.cx/sv/library/adipotide; sk: https://peptides.cx/sk/library/adipotide; lt: https://peptides.cx/lt/library/adipotide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: None established; primate studies showed renal toxicity. Preclinical evidence: Weight loss with nephrotoxicity reported. Safety summary: Documented kidney toxicity in primate studies. Considered unsafe for human use. Regulatory context: Not an approved medicine. Experimental; significant safety concerns. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/22072637/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Thymalin Name: Thymalin Canonical URL: https://peptides.cx/library/thymalin Localized URLs: en: https://peptides.cx/library/thymalin; de: https://peptides.cx/de/library/thymalin; fr: https://peptides.cx/fr/library/thymalin; it: https://peptides.cx/it/library/thymalin; es: https://peptides.cx/es/library/thymalin; el: https://peptides.cx/el/library/thymalin; pl: https://peptides.cx/pl/library/thymalin; nl: https://peptides.cx/nl/library/thymalin; cs: https://peptides.cx/cs/library/thymalin; ro: https://peptides.cx/ro/library/thymalin; bg: https://peptides.cx/bg/library/thymalin; fi: https://peptides.cx/fi/library/thymalin; sv: https://peptides.cx/sv/library/thymalin; sk: https://peptides.cx/sk/library/thymalin; lt: https://peptides.cx/lt/library/thymalin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Regional clinical use; limited independent replication. Preclinical evidence: Immune effects reported. Safety summary: Research-market material is unverified; not a validated therapy where unapproved. Regulatory context: Used as a medicine in some countries; not approved in the EU/US. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/14523363/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Pinealon Name: Pinealon Canonical URL: https://peptides.cx/library/pinealon Localized URLs: en: https://peptides.cx/library/pinealon; de: https://peptides.cx/de/library/pinealon; fr: https://peptides.cx/fr/library/pinealon; it: https://peptides.cx/it/library/pinealon; es: https://peptides.cx/es/library/pinealon; el: https://peptides.cx/el/library/pinealon; pl: https://peptides.cx/pl/library/pinealon; nl: https://peptides.cx/nl/library/pinealon; cs: https://peptides.cx/cs/library/pinealon; ro: https://peptides.cx/ro/library/pinealon; bg: https://peptides.cx/bg/library/pinealon; fi: https://peptides.cx/fi/library/pinealon; sv: https://peptides.cx/sv/library/pinealon; sk: https://peptides.cx/sk/library/pinealon; lt: https://peptides.cx/lt/library/pinealon Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: Weak; limited independent replication. Preclinical evidence: Some neuroprotective claims from originating groups. Safety summary: Human safety data is weak; treat claims with caution. Regulatory context: Not an approved medicine. Research status. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/21978084/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Argireline Name: Argireline Canonical URL: https://peptides.cx/library/argireline Localized URLs: en: https://peptides.cx/library/argireline; de: https://peptides.cx/de/library/argireline; fr: https://peptides.cx/fr/library/argireline; it: https://peptides.cx/it/library/argireline; es: https://peptides.cx/es/library/argireline; el: https://peptides.cx/el/library/argireline; pl: https://peptides.cx/pl/library/argireline; nl: https://peptides.cx/nl/library/argireline; cs: https://peptides.cx/cs/library/argireline; ro: https://peptides.cx/ro/library/argireline; bg: https://peptides.cx/bg/library/argireline; fi: https://peptides.cx/fi/library/argireline; sv: https://peptides.cx/sv/library/argireline; sk: https://peptides.cx/sk/library/argireline; lt: https://peptides.cx/lt/library/argireline Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: B — Human evidence exists but is limited. Human evidence: Cosmetic studies report modest improvements in the appearance of fine lines. Preclinical evidence: Not the primary evidence base; mechanistic/in-vitro data exists. Safety summary: Generally well tolerated topically. This is a cosmetic ingredient, not an injectable. Regulatory context: Widely used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/23417317/, https://pubmed.ncbi.nlm.nih.gov/40565185/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Matrixyl Name: Matrixyl Canonical URL: https://peptides.cx/library/matrixyl Localized URLs: en: https://peptides.cx/library/matrixyl; de: https://peptides.cx/de/library/matrixyl; fr: https://peptides.cx/fr/library/matrixyl; it: https://peptides.cx/it/library/matrixyl; es: https://peptides.cx/es/library/matrixyl; el: https://peptides.cx/el/library/matrixyl; pl: https://peptides.cx/pl/library/matrixyl; nl: https://peptides.cx/nl/library/matrixyl; cs: https://peptides.cx/cs/library/matrixyl; ro: https://peptides.cx/ro/library/matrixyl; bg: https://peptides.cx/bg/library/matrixyl; fi: https://peptides.cx/fi/library/matrixyl; sv: https://peptides.cx/sv/library/matrixyl; sk: https://peptides.cx/sk/library/matrixyl; lt: https://peptides.cx/lt/library/matrixyl Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: None verified Offer last checked: No peptide-specific offer Evidence grade: B — Human evidence exists but is limited. Human evidence: Cosmetic studies report improvements in skin appearance. Preclinical evidence: Mechanistic/in-vitro support. Safety summary: Generally well tolerated topically; a cosmetic ingredient, not an injectable. Regulatory context: Widely used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/18492182/, https://pmc.ncbi.nlm.nih.gov/articles/PMC10005804/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## SNAP-8 Name: SNAP-8 Canonical URL: https://peptides.cx/library/snap-8 Localized URLs: en: https://peptides.cx/library/snap-8; de: https://peptides.cx/de/library/snap-8; fr: https://peptides.cx/fr/library/snap-8; it: https://peptides.cx/it/library/snap-8; es: https://peptides.cx/es/library/snap-8; el: https://peptides.cx/el/library/snap-8; pl: https://peptides.cx/pl/library/snap-8; nl: https://peptides.cx/nl/library/snap-8; cs: https://peptides.cx/cs/library/snap-8; ro: https://peptides.cx/ro/library/snap-8; bg: https://peptides.cx/bg/library/snap-8; fi: https://peptides.cx/fi/library/snap-8; sv: https://peptides.cx/sv/library/snap-8; sk: https://peptides.cx/sk/library/snap-8; lt: https://peptides.cx/lt/library/snap-8 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited cosmetic data. Preclinical evidence: Mechanistic/in-vitro data. Safety summary: Topical cosmetic ingredient; generally well tolerated. Regulatory context: Used as a topical cosmetic ingredient. Cosmetic use is broadly permitted. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7662462/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## VIP Name: VIP Canonical URL: https://peptides.cx/library/vip Localized URLs: en: https://peptides.cx/library/vip; de: https://peptides.cx/de/library/vip; fr: https://peptides.cx/fr/library/vip; it: https://peptides.cx/it/library/vip; es: https://peptides.cx/es/library/vip; el: https://peptides.cx/el/library/vip; pl: https://peptides.cx/pl/library/vip; nl: https://peptides.cx/nl/library/vip; cs: https://peptides.cx/cs/library/vip; ro: https://peptides.cx/ro/library/vip; bg: https://peptides.cx/bg/library/vip; fi: https://peptides.cx/fi/library/vip; sv: https://peptides.cx/sv/library/vip; sk: https://peptides.cx/sk/library/vip; lt: https://peptides.cx/lt/library/vip Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited outside specific medical contexts. Preclinical evidence: Well characterised physiologically. Safety summary: Can affect blood pressure; appropriate only under medical supervision. Regulatory context: Not an approved general-use medicine; used in specific medical/diagnostic contexts. Last editorial review: 2026-06-01 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/36044317/, https://pubmed.ncbi.nlm.nih.gov/37348524/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Cagrilintide Name: Cagrilintide Canonical URL: https://peptides.cx/library/cagrilintide Localized URLs: en: https://peptides.cx/library/cagrilintide; de: https://peptides.cx/de/library/cagrilintide; fr: https://peptides.cx/fr/library/cagrilintide; it: https://peptides.cx/it/library/cagrilintide; es: https://peptides.cx/es/library/cagrilintide; el: https://peptides.cx/el/library/cagrilintide; pl: https://peptides.cx/pl/library/cagrilintide; nl: https://peptides.cx/nl/library/cagrilintide; cs: https://peptides.cx/cs/library/cagrilintide; ro: https://peptides.cx/ro/library/cagrilintide; bg: https://peptides.cx/bg/library/cagrilintide; fi: https://peptides.cx/fi/library/cagrilintide; sv: https://peptides.cx/sv/library/cagrilintide; sk: https://peptides.cx/sk/library/cagrilintide; lt: https://peptides.cx/lt/library/cagrilintide Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: A randomised phase 2 dose-finding trial (Lancet, 2021) reported dose-dependent weight reduction with cagrilintide monotherapy in people with overweight or obesity. The phase 3 REDEFINE 1 trial (NEJM, 2025) tested it combined with semaglutide and found clinically meaningful weight loss versus placebo. Cagrilintide alone is not approved, and long-term outcomes and safety of monotherapy are not established. Preclinical evidence: Characterised in preclinical obesity models, where amylin-receptor agonism reduced food intake and body weight. Safety summary: Across trials the most common adverse events were gastrointestinal (nausea, constipation, diarrhoea) and injection-site reactions. As an investigational product its full long-term safety profile is not established, and research-market material is not a quality-assured or pharmacist-dispensed medicine. Regulatory context: Investigational; not an approved medicine in the EU or US as of mid-2026. Developed by Novo Nordisk; the fixed combination with semaglutide (CagriSema) is under regulatory review. Investigational product, not a general-use compound. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/34798060/, https://pubmed.ncbi.nlm.nih.gov/40544433/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## ARA-290 Name: ARA-290 Canonical URL: https://peptides.cx/library/ara-290 Localized URLs: en: https://peptides.cx/library/ara-290; de: https://peptides.cx/de/library/ara-290; fr: https://peptides.cx/fr/library/ara-290; it: https://peptides.cx/it/library/ara-290; es: https://peptides.cx/es/library/ara-290; el: https://peptides.cx/el/library/ara-290; pl: https://peptides.cx/pl/library/ara-290; nl: https://peptides.cx/nl/library/ara-290; cs: https://peptides.cx/cs/library/ara-290; ro: https://peptides.cx/ro/library/ara-290; bg: https://peptides.cx/bg/library/ara-290; fi: https://peptides.cx/fi/library/ara-290; sv: https://peptides.cx/sv/library/ara-290; sk: https://peptides.cx/sk/library/ara-290; lt: https://peptides.cx/lt/library/ara-290 Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Two small randomised, placebo-controlled phase 2 trials in sarcoidosis-associated small-fibre neuropathy (Molecular Medicine, 2013; Investigative Ophthalmology & Visual Science, 2017) reported improvements in corneal nerve-fibre measures and neuropathic symptoms over 28 days. These studies were small, short, and relied on surrogate endpoints; no phase 3 confirmation exists and outcomes for other conditions are unproven. Preclinical evidence: Preclinical models of neuropathy, ischaemia, and inflammation reported tissue-protective and anti-inflammatory effects, which motivated the human trials. Safety summary: In the short phase 2 trials it was generally well tolerated with no serious adverse events reported, but these involved few participants over about four weeks. Long-term safety is unknown, and it is not a licensed medicine or quality-assured product. Regulatory context: Not approved by the FDA, EMA, or any major regulator for any indication. It received orphan-drug and fast-track designations for sarcoidosis, but these are development incentives, not approvals. Clinical development stalled after phase 2; sold only as a research chemical, not authorised for human use. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/, https://pubmed.ncbi.nlm.nih.gov/28475703/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Oxytocin Name: Oxytocin Canonical URL: https://peptides.cx/library/oxytocin Localized URLs: en: https://peptides.cx/library/oxytocin; de: https://peptides.cx/de/library/oxytocin; fr: https://peptides.cx/fr/library/oxytocin; it: https://peptides.cx/it/library/oxytocin; es: https://peptides.cx/es/library/oxytocin; el: https://peptides.cx/el/library/oxytocin; pl: https://peptides.cx/pl/library/oxytocin; nl: https://peptides.cx/nl/library/oxytocin; cs: https://peptides.cx/cs/library/oxytocin; ro: https://peptides.cx/ro/library/oxytocin; bg: https://peptides.cx/bg/library/oxytocin; fi: https://peptides.cx/fi/library/oxytocin; sv: https://peptides.cx/sv/library/oxytocin; sk: https://peptides.cx/sk/library/oxytocin; lt: https://peptides.cx/lt/library/oxytocin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Efficacy is well established and approved for its obstetric indications. For the popular behavioural uses — intranasal oxytocin for autism, trust, or social cognition — the evidence is inconsistent: a meta-analysis of randomised trials (Psychoneuroendocrinology, 2018) found at most small effects and largely inconclusive results, limited by small samples and heterogeneity. Preclinical evidence: Extensively studied in animal models of pair-bonding, maternal behaviour, and social affiliation. Safety summary: Intravenous obstetric use carries significant risks, including uterine hyperstimulation, water intoxication with hyponatraemia, and adverse fetal effects, and is only appropriate under medical supervision. Intranasal research doses are generally reported to cause mild, transient effects, but that form is not a licensed product. Regulatory context: An approved prescription medicine in the EU and US for obstetric use — induction or augmentation of labour and control of postpartum bleeding — administered under medical supervision. The widely discussed intranasal and behavioural uses are not approved and remain investigational. Prescription-only. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=969d5b35-0add-4c23-9605-6a5b6ab65c95, https://pubmed.ncbi.nlm.nih.gov/29032324/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## HCG Name: HCG Canonical URL: https://peptides.cx/library/hcg Localized URLs: en: https://peptides.cx/library/hcg; de: https://peptides.cx/de/library/hcg; fr: https://peptides.cx/fr/library/hcg; it: https://peptides.cx/it/library/hcg; es: https://peptides.cx/es/library/hcg; el: https://peptides.cx/el/library/hcg; pl: https://peptides.cx/pl/library/hcg; nl: https://peptides.cx/nl/library/hcg; cs: https://peptides.cx/cs/library/hcg; ro: https://peptides.cx/ro/library/hcg; bg: https://peptides.cx/bg/library/hcg; fi: https://peptides.cx/fi/library/hcg; sv: https://peptides.cx/sv/library/hcg; sk: https://peptides.cx/sk/library/hcg; lt: https://peptides.cx/lt/library/hcg Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Evidence supports its approved endocrine and fertility indications. Off-label use in men for hypogonadism or fertility preservation has supportive but limited data from mostly small studies. Use for weight loss is not supported: the approved label states there is no substantial evidence it aids weight loss and that it has no known effect on fat mobilisation, appetite, or fat distribution. Preclinical evidence: Gonadotropic effects on the testis and ovary are well characterised across species. Safety summary: A prescription hormone requiring medical supervision. Reported risks include ovarian hyperstimulation syndrome in women, thromboembolism, precocious puberty in treated children, and gynaecomastia in men. Non-medical or 'diet' use is unsupervised and carries these risks without benefit. Regulatory context: An approved prescription medicine in the EU and US for prepubertal cryptorchidism, selected cases of male hypogonadotropic hypogonadism, and induction of ovulation in women pretreated with menotropins. The FDA-approved label explicitly states it is not effective for weight loss or obesity. Prescription-only. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc604794-6dd6-43a7-85fa-2f04ed325c33, https://pmc.ncbi.nlm.nih.gov/articles/PMC6087849/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## HGH Name: HGH Canonical URL: https://peptides.cx/library/hgh Localized URLs: en: https://peptides.cx/library/hgh; de: https://peptides.cx/de/library/hgh; fr: https://peptides.cx/fr/library/hgh; it: https://peptides.cx/it/library/hgh; es: https://peptides.cx/es/library/hgh; el: https://peptides.cx/el/library/hgh; pl: https://peptides.cx/pl/library/hgh; nl: https://peptides.cx/nl/library/hgh; cs: https://peptides.cx/cs/library/hgh; ro: https://peptides.cx/ro/library/hgh; bg: https://peptides.cx/bg/library/hgh; fi: https://peptides.cx/fi/library/hgh; sv: https://peptides.cx/sv/library/hgh; sk: https://peptides.cx/sk/library/hgh; lt: https://peptides.cx/lt/library/hgh Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: A — Approved medical use or strong clinical evidence. Human evidence: Strong clinical evidence and regulatory approval support its use in genuine growth-hormone deficiency and defined paediatric growth disorders. For anti-ageing or body-composition use in healthy adults, a systematic review (Annals of Internal Medicine, 2007) found only small body-composition changes offset by higher rates of adverse events, and concluded it cannot be recommended as an anti-ageing therapy. Preclinical evidence: Growth, metabolic, and IGF-1-axis effects are extensively characterised across species. Safety summary: A prescription hormone with significant risks, including fluid retention, joint and muscle pain, carpal tunnel syndrome, and insulin resistance or impaired glucose tolerance. It is contraindicated in acute critical illness and active malignancy, with an increased-mortality signal in critically ill patients. Non-medical use is unsafe and, in the US, unlawful. Regulatory context: An approved prescription medicine (somatropin) in the EU and US for defined growth-hormone-deficiency and growth disorders in children and adults. In the US, distributing HGH for non-approved uses such as anti-ageing or athletic enhancement is specifically prohibited by federal law (21 U.S.C. §333(e)). Prescription-only. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765, https://pubmed.ncbi.nlm.nih.gov/17227934/, https://www.law.cornell.edu/uscode/text/21/333 Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Adamax Name: Adamax Canonical URL: https://peptides.cx/library/adamax Localized URLs: en: https://peptides.cx/library/adamax; de: https://peptides.cx/de/library/adamax; fr: https://peptides.cx/fr/library/adamax; it: https://peptides.cx/it/library/adamax; es: https://peptides.cx/es/library/adamax; el: https://peptides.cx/el/library/adamax; pl: https://peptides.cx/pl/library/adamax; nl: https://peptides.cx/nl/library/adamax; cs: https://peptides.cx/cs/library/adamax; ro: https://peptides.cx/ro/library/adamax; bg: https://peptides.cx/bg/library/adamax; fi: https://peptides.cx/fi/library/adamax; sv: https://peptides.cx/sv/library/adamax; sk: https://peptides.cx/sk/library/adamax; lt: https://peptides.cx/lt/library/adamax Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: There is no peer-reviewed human research on Adamax. No clinical trials, pharmacokinetic studies, or controlled cognitive-outcome data exist. Reported effects come from vendor pages and user forums only. Preclinical evidence: No peer-reviewed animal studies of Adamax specifically could be located. Related peptides such as Semax have their own literature, but those findings cannot be assumed to transfer to a differently modified, poorly characterised compound. Safety summary: The safety profile of Adamax is unknown. Because it is unapproved and its composition, purity, and pharmacology are not established, its potential adverse effects and interactions cannot be characterised. Regulatory context: Not approved for human use in any jurisdiction. Sold as a 'research chemical.' New Zealand's Medsafe recorded it in border seizures and, in a June 2025 submission, proposed classifying ACTH-analogue nootropic peptides (naming Adamax and Semax) as prescription medicines. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.medsafe.govt.nz/profs/class/Agendas/Agen74/5.7Peptides.pdf Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Cartalax Name: Cartalax Canonical URL: https://peptides.cx/library/cartalax Localized URLs: en: https://peptides.cx/library/cartalax; de: https://peptides.cx/de/library/cartalax; fr: https://peptides.cx/fr/library/cartalax; it: https://peptides.cx/it/library/cartalax; es: https://peptides.cx/es/library/cartalax; el: https://peptides.cx/el/library/cartalax; pl: https://peptides.cx/pl/library/cartalax; nl: https://peptides.cx/nl/library/cartalax; cs: https://peptides.cx/cs/library/cartalax; ro: https://peptides.cx/ro/library/cartalax; bg: https://peptides.cx/bg/library/cartalax; fi: https://peptides.cx/fi/library/cartalax; sv: https://peptides.cx/sv/library/cartalax; sk: https://peptides.cx/sk/library/cartalax; lt: https://peptides.cx/lt/library/cartalax Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: There are no controlled human trials of Cartalax. The peer-reviewed work on the AED peptide is in vitro and comes largely from one research group. No published clinical evidence supports the marketed cartilage or joint-repair claims. Preclinical evidence: Direct, independently replicated animal efficacy studies of Cartalax for cartilage are scarce to absent in the indexed literature; most supporting material is mechanistic or review-level rather than controlled in vivo data. Safety summary: Human safety data are lacking. As an unapproved peptide sold for research use, its purity, long-term effects, and interactions are not established. Regulatory context: Not approved as a drug in any jurisdiction (no FDA, EMA, or comparable marketing authorisation). Sold as a 'research chemical' / peptide bioregulator. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/30791821/, https://pubmed.ncbi.nlm.nih.gov/34834147/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## AHK-Cu Name: AHK-Cu Canonical URL: https://peptides.cx/library/ahk-cu Localized URLs: en: https://peptides.cx/library/ahk-cu; de: https://peptides.cx/de/library/ahk-cu; fr: https://peptides.cx/fr/library/ahk-cu; it: https://peptides.cx/it/library/ahk-cu; es: https://peptides.cx/es/library/ahk-cu; el: https://peptides.cx/el/library/ahk-cu; pl: https://peptides.cx/pl/library/ahk-cu; nl: https://peptides.cx/nl/library/ahk-cu; cs: https://peptides.cx/cs/library/ahk-cu; ro: https://peptides.cx/ro/library/ahk-cu; bg: https://peptides.cx/bg/library/ahk-cu; fi: https://peptides.cx/fi/library/ahk-cu; sv: https://peptides.cx/sv/library/ahk-cu; sk: https://peptides.cx/sk/library/ahk-cu; lt: https://peptides.cx/lt/library/ahk-cu Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Human clinical evidence for AHK-Cu is very limited. The most-cited study used cultured human cells and excised follicles (in vitro/ex vivo), not living participants. Well-controlled clinical trials specifically on AHK-Cu are lacking, and some efficacy figures circulating online are not supported by locatable peer-reviewed trials. Preclinical evidence: Dedicated animal-model data for AHK-Cu are sparse in the indexed literature; most mechanistic support comes from cell-culture and ex vivo tissue work. Safety summary: Topical copper peptides are generally regarded as well tolerated in cosmetic use, but AHK-Cu itself has limited safety documentation, and there is little human data for injectable or systemic use. Local skin reactions are plausible with topical application. Regulatory context: Not approved as a drug. The tripeptide appears as a cosmetic ingredient (INCI 'Copper Tripeptide-3') in topical products; injectable or systemic use is unapproved and sold only as a 'research chemical.' Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/17703734/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## 5-Amino-1MQ Name: 5-Amino-1MQ Canonical URL: https://peptides.cx/library/5-amino-1mq Localized URLs: en: https://peptides.cx/library/5-amino-1mq; de: https://peptides.cx/de/library/5-amino-1mq; fr: https://peptides.cx/fr/library/5-amino-1mq; it: https://peptides.cx/it/library/5-amino-1mq; es: https://peptides.cx/es/library/5-amino-1mq; el: https://peptides.cx/el/library/5-amino-1mq; pl: https://peptides.cx/pl/library/5-amino-1mq; nl: https://peptides.cx/nl/library/5-amino-1mq; cs: https://peptides.cx/cs/library/5-amino-1mq; ro: https://peptides.cx/ro/library/5-amino-1mq; bg: https://peptides.cx/bg/library/5-amino-1mq; fi: https://peptides.cx/fi/library/5-amino-1mq; sv: https://peptides.cx/sv/library/5-amino-1mq; sk: https://peptides.cx/sk/library/5-amino-1mq; lt: https://peptides.cx/lt/library/5-amino-1mq Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: There are no published human clinical trials of 5-Amino-1MQ. No peer-reviewed human efficacy or safety data exist; all controlled evidence is from rodents and cell culture. Preclinical evidence: In diet-induced obese mice, a lead NNMT inhibitor (5-amino-1MQ) reduced body weight and white-adipose mass and lowered plasma cholesterol without changing food intake in that study. The findings are preclinical and have not been confirmed in humans. Safety summary: Human safety is unknown. Because it is unapproved and untested in people, its adverse-effect profile, long-term risks, and drug interactions are not established. Regulatory context: Not approved for human use in any jurisdiction and not a recognised dietary supplement. A small molecule, not a peptide. Sold only as a 'research chemical.' Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/29155147/, https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## AICAR Name: AICAR Canonical URL: https://peptides.cx/library/aicar Localized URLs: en: https://peptides.cx/library/aicar; de: https://peptides.cx/de/library/aicar; fr: https://peptides.cx/fr/library/aicar; it: https://peptides.cx/it/library/aicar; es: https://peptides.cx/es/library/aicar; el: https://peptides.cx/el/library/aicar; pl: https://peptides.cx/pl/library/aicar; nl: https://peptides.cx/nl/library/aicar; cs: https://peptides.cx/cs/library/aicar; ro: https://peptides.cx/ro/library/aicar; bg: https://peptides.cx/bg/library/aicar; fi: https://peptides.cx/fi/library/aicar; sv: https://peptides.cx/sv/library/aicar; sk: https://peptides.cx/sk/library/aicar; lt: https://peptides.cx/lt/library/aicar Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: AICAR (as acadesine) has been studied in large human trials — but for cardioprotection during coronary artery bypass surgery, not fitness. The pivotal RED-CABG randomised trial (~3,000 patients) was stopped for futility and showed no benefit. No human evidence supports its marketed performance or fat-loss uses, and it has never been approved. Preclinical evidence: Rodent studies popularised AICAR as an 'exercise mimetic,' reporting increased endurance and metabolic changes. These animal findings drove interest but did not translate into demonstrated human benefit. Safety summary: AICAR is unapproved for human use and prohibited in sport. In cardiac-surgery trials it was tolerated short-term under medical supervision, but higher-dose studies raised concerns such as kidney toxicity. Long-term safety outside a trial setting is not established. Regulatory context: A small-molecule AMPK activator, not a peptide. Not approved for human use in any jurisdiction (development as acadesine was discontinued). Prohibited at all times in sport by WADA as an S4 hormone and metabolic modulator. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pubmed.ncbi.nlm.nih.gov/22782417/, https://pubmed.ncbi.nlm.nih.gov/34064363/, https://www.usada.org/spirit-of-sport/aicar-and-other-prohibited-amp-activated-protein-kinase-activators/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Glutathione Name: Glutathione Canonical URL: https://peptides.cx/library/glutathione Localized URLs: en: https://peptides.cx/library/glutathione; de: https://peptides.cx/de/library/glutathione; fr: https://peptides.cx/fr/library/glutathione; it: https://peptides.cx/it/library/glutathione; es: https://peptides.cx/es/library/glutathione; el: https://peptides.cx/el/library/glutathione; pl: https://peptides.cx/pl/library/glutathione; nl: https://peptides.cx/nl/library/glutathione; cs: https://peptides.cx/cs/library/glutathione; ro: https://peptides.cx/ro/library/glutathione; bg: https://peptides.cx/bg/library/glutathione; fi: https://peptides.cx/fi/library/glutathione; sv: https://peptides.cx/sv/library/glutathione; sk: https://peptides.cx/sk/library/glutathione; lt: https://peptides.cx/lt/library/glutathione Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Mixed and generally weak for the popular claims. Some randomized trials show that oral glutathione can raise body glutathione stores over months, while others found no change over shorter periods — results vary with dose, duration, and formulation. Evidence that oral or IV glutathione meaningfully lightens skin, 'detoxifies', or slows aging is limited, short-term, and often low-quality. Intravenous use for skin lightening is the least supported and most scrutinized: one reviewed dataset reported adverse events in about a third of participants, including liver dysfunction and a case of anaphylaxis. Preclinical evidence: Animal and in vitro work established glutathione's core biology — antioxidant defense, detoxification, and redox signaling — and provides the mechanistic rationale for tyrosinase inhibition. This foundation is solid for the internal biology but does not demonstrate that supplementation produces the cosmetic outcomes marketed to consumers. Safety summary: Oral glutathione is generally well tolerated in trials, with mostly mild, transient gastrointestinal effects. The main safety concerns attach to injectable and intravenous use, especially for skin lightening: documented risks include liver and kidney effects, severe allergic reactions including anaphylaxis, and — because many products are compounded from non-sterile material — infection and contamination. Regulators including the US FDA have flagged injectable skin-lightening products as unapproved and potentially unsafe. Regulatory context: Endogenous tripeptide sold as an oral dietary supplement in the US and much of the EU. No intravenous or injectable glutathione product is approved by the FDA or EMA. The US FDA has not approved glutathione for skin lightening and has warned that injectable skin-lightening products, including those containing glutathione, are unapproved and may be unsafe and ineffective. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC2696075/, https://pubmed.ncbi.nlm.nih.gov/24791752/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11862975/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## NAD+ Name: NAD+ Canonical URL: https://peptides.cx/library/nad-plus Localized URLs: en: https://peptides.cx/library/nad-plus; de: https://peptides.cx/de/library/nad-plus; fr: https://peptides.cx/fr/library/nad-plus; it: https://peptides.cx/it/library/nad-plus; es: https://peptides.cx/es/library/nad-plus; el: https://peptides.cx/el/library/nad-plus; pl: https://peptides.cx/pl/library/nad-plus; nl: https://peptides.cx/nl/library/nad-plus; cs: https://peptides.cx/cs/library/nad-plus; ro: https://peptides.cx/ro/library/nad-plus; bg: https://peptides.cx/bg/library/nad-plus; fi: https://peptides.cx/fi/library/nad-plus; sv: https://peptides.cx/sv/library/nad-plus; sk: https://peptides.cx/sk/library/nad-plus; lt: https://peptides.cx/lt/library/nad-plus Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: C — Mostly early human, animal, or mechanistic data. Human evidence: Limited, especially for the anti-aging claims that drive sales. Trials show oral precursors such as NR and NMN can reliably raise blood NAD+ levels and are generally safe short-term, but most measured clinical outcomes — glucose and lipid metabolism, muscle strength, physical function — have not improved significantly versus placebo. Direct IV NAD+ is barely studied: small pilot work has tracked its metabolism during infusion, but no adequately powered trials support IV NAD+ for anti-aging or any wellness outcome. Preclinical evidence: Preclinical studies in rodents and cell models are the main source of enthusiasm: raising NAD+ or its precursors has improved metabolic and some age-related measures in animals. However, human NAD+ dynamics differ from rodents, and these animal results have not translated cleanly into demonstrated clinical benefit in people. Safety summary: Oral NR and NMN have been well tolerated in short-term trials, with generally mild side effects. Intravenous NAD+ is used at clinics but has little formal safety characterization; faster infusions are commonly associated with transient discomfort such as flushing, nausea, chest tightness, and cramping. Long-term safety of sustained NAD+ elevation in humans is not established. Regulatory context: NAD+ is a coenzyme, not a peptide and not an approved drug. No intravenous or injectable NAD+ product is approved by the FDA or EMA for anti-aging, cognitive, or wellness use; IV NAD+ is offered at clinics as an unapproved application. Among precursors, nicotinamide riboside (NR) is sold as a dietary supplement, whereas the US FDA has taken the position that NMN is excluded from the dietary-supplement definition. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/, https://pmc.ncbi.nlm.nih.gov/articles/PMC7558103/, https://pubmed.ncbi.nlm.nih.gov/41083806/ Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Melatonin Name: Melatonin Canonical URL: https://peptides.cx/library/melatonin Localized URLs: en: https://peptides.cx/library/melatonin; de: https://peptides.cx/de/library/melatonin; fr: https://peptides.cx/fr/library/melatonin; it: https://peptides.cx/it/library/melatonin; es: https://peptides.cx/es/library/melatonin; el: https://peptides.cx/el/library/melatonin; pl: https://peptides.cx/pl/library/melatonin; nl: https://peptides.cx/nl/library/melatonin; cs: https://peptides.cx/cs/library/melatonin; ro: https://peptides.cx/ro/library/melatonin; bg: https://peptides.cx/bg/library/melatonin; fi: https://peptides.cx/fi/library/melatonin; sv: https://peptides.cx/sv/library/melatonin; sk: https://peptides.cx/sk/library/melatonin; lt: https://peptides.cx/lt/library/melatonin Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: B — Human evidence exists but is limited. Human evidence: Comparatively well studied. Meta-analyses of randomized trials in primary sleep disorders find that melatonin modestly shortens the time to fall asleep (on the order of several minutes), modestly increases total sleep time, and improves subjective sleep quality; the absolute benefit is smaller than for standard prescription hypnotics. Evidence is stronger for circadian problems such as jet lag than for chronic insomnia — the American Academy of Sleep Medicine issued a weak recommendation against melatonin for chronic insomnia. A practical problem is product quality: an analysis of US melatonin gummies found actual content ranging from roughly three-quarters to more than three times the labeled amount. Preclinical evidence: Animal studies underpin melatonin's role as a circadian signaling hormone and characterize its MT1/MT2 receptor pharmacology, phase-shifting effects, and antioxidant properties. These models explain how and when melatonin influences sleep timing but are not the primary basis for its human use claims. Safety summary: Melatonin has a favorable short-term safety profile, which is one reason it is often preferred over conventional hypnotics. Common effects are mild and include daytime drowsiness, headache, and dizziness. Because it is a hormone and because OTC labeling can be inaccurate, caution is reasonable for children, during pregnancy, and with long-term use. It can cause drowsiness and should not be combined with alcohol or used before driving. Regulatory context: A hormone, not a peptide. Regulatory status varies by country: sold over-the-counter as a dietary supplement in the US (not FDA-approved for any medical condition), but prescription-only in the UK and several EU countries. The EMA has approved a prolonged-release melatonin product (Circadin) as a prescription treatment for primary insomnia in adults aged 55 and older. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: https://www.ncbi.nlm.nih.gov/books/NBK534823/, https://pubmed.ncbi.nlm.nih.gov/23691095/, https://www.ema.europa.eu/en/medicines/human/EPAR/circadin Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## GLOW (blend) Name: GLOW (blend) Canonical URL: https://peptides.cx/library/glow Localized URLs: en: https://peptides.cx/library/glow; de: https://peptides.cx/de/library/glow; fr: https://peptides.cx/fr/library/glow; it: https://peptides.cx/it/library/glow; es: https://peptides.cx/es/library/glow; el: https://peptides.cx/el/library/glow; pl: https://peptides.cx/pl/library/glow; nl: https://peptides.cx/nl/library/glow; cs: https://peptides.cx/cs/library/glow; ro: https://peptides.cx/ro/library/glow; bg: https://peptides.cx/bg/library/glow; fi: https://peptides.cx/fi/library/glow; sv: https://peptides.cx/sv/library/glow; sk: https://peptides.cx/sk/library/glow; lt: https://peptides.cx/lt/library/glow Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: None for the blend. No clinical trials have studied this GHK-Cu / BPC-157 / TB-500 combination in humans for safety or effectiveness. The individual components also lack robust human evidence: GHK-Cu's human data is largely limited to topical cosmetic use, and BPC-157 and TB-500 have essentially no adequately controlled human trials. Combining unproven agents does not create evidence — it removes the ability to tell which ingredient is responsible for any effect. Preclinical evidence: Only indirect. Each component has some preclinical (mostly rodent or in vitro) literature, but there are no animal studies of this specific fixed-ratio blend, and preclinical results for the components have not been confirmed in humans. Safety summary: The safety of the blend is unknown. No formal human safety data exist for the combination, and fixed-ratio blends make it harder to identify the source of any adverse reaction or to adjust exposure to a single ingredient. Products are sold as research chemicals with variable composition and purity, adding contamination and mislabeling risk on top of the unknowns of each peptide. Regulatory context: Not an approved medicine anywhere. GLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Its individual components (GHK-Cu, BPC-157, TB-500) are themselves unapproved as drugs, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: No suitable primary study or review specific to this entry was identified during the last editorial review. Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## KLOW (blend) Name: KLOW (blend) Canonical URL: https://peptides.cx/library/klow Localized URLs: en: https://peptides.cx/library/klow; de: https://peptides.cx/de/library/klow; fr: https://peptides.cx/fr/library/klow; it: https://peptides.cx/it/library/klow; es: https://peptides.cx/es/library/klow; el: https://peptides.cx/el/library/klow; pl: https://peptides.cx/pl/library/klow; nl: https://peptides.cx/nl/library/klow; cs: https://peptides.cx/cs/library/klow; ro: https://peptides.cx/ro/library/klow; bg: https://peptides.cx/bg/library/klow; fi: https://peptides.cx/fi/library/klow; sv: https://peptides.cx/sv/library/klow; sk: https://peptides.cx/sk/library/klow; lt: https://peptides.cx/lt/library/klow Transactional search intent: Compare checked vendor information while keeping purchase data separate from scientific assessment. Available vendors: Crystal Peptides Offer last checked: 2026-07-18 Evidence grade: D — Anecdotal or insufficient evidence. Human evidence: None for the blend. No clinical trials have evaluated this KPV / GHK-Cu / BPC-157 / TB-500 (with or without LL-37) combination in humans. The components individually also lack robust human evidence for the marketed claims. Adding more unproven peptides increases uncertainty rather than confidence. Preclinical evidence: Only indirect and component-level. KPV has anti-inflammatory activity in cell and rodent models; LL-37 is extensively studied in immunology; and GHK-Cu, BPC-157, and TB-500 each have preclinical repair-related literature. But no animal studies exist for this specific fixed blend. Safety summary: The safety of the blend is unknown. There is no human safety data for the combination, and including an immunologically active peptide such as LL-37 alongside several other unapproved agents raises the number of ways an adverse reaction could occur while removing any way to isolate the cause. Products are sold as research chemicals with variable composition and purity. Regulatory context: Not an approved medicine anywhere. KLOW is a research-market blend sold under 'research use only' labeling and is not approved by the FDA, EMA, or any regulator. Every component is itself an unapproved drug, and BPC-157 and TB-500 are prohibited in sport under the World Anti-Doping Agency (WADA) list. Last editorial review: 2026-07-18 Written by: peptides.cx Editorial Team Reviewed by: No named scientific reviewer assigned Sources: No suitable primary study or review specific to this entry was identified during the last editorial review. Known unknowns: Long-term safety, product quality and efficacy remain limited to the evidence described above; absent data is not inferred. Affiliate disclosure: Vendor links may be sponsored. Commercial relationships do not determine evidence or safety ratings. ## Head-to-head comparisons - [BPC-157 vs TB-500 / Thymosin Beta-4](https://peptides.cx/compare/bpc-157-vs-tb-500) - [Semaglutide vs Tirzepatide](https://peptides.cx/compare/semaglutide-vs-tirzepatide) - [Tirzepatide vs Retatrutide](https://peptides.cx/compare/tirzepatide-vs-retatrutide) - [Ipamorelin vs CJC-1295](https://peptides.cx/compare/ipamorelin-vs-cjc-1295) - [GHRP-2 vs GHRP-6](https://peptides.cx/compare/ghrp-2-vs-ghrp-6) - [Semax vs Selank](https://peptides.cx/compare/semax-vs-selank) - [MOTS-c vs SS-31 (Elamipretide)](https://peptides.cx/compare/mots-c-vs-ss-31) - [Melanotan I vs Melanotan II](https://peptides.cx/compare/melanotan-1-vs-melanotan-2) - [CJC-1295 vs Sermorelin](https://peptides.cx/compare/cjc-1295-vs-sermorelin) - [IGF-1 LR3 vs MGF / PEG-MGF](https://peptides.cx/compare/igf-1-lr3-vs-mgf) - [Tesamorelin vs Sermorelin](https://peptides.cx/compare/tesamorelin-vs-sermorelin) - [Epitalon vs Thymalin](https://peptides.cx/compare/epitalon-vs-thymalin) - [BPC-157 vs GHK-Cu](https://peptides.cx/compare/bpc-157-vs-ghk-cu) - [Kisspeptin-10 vs Gonadorelin](https://peptides.cx/compare/kisspeptin-10-vs-gonadorelin) - [Hexarelin vs GHRP-2](https://peptides.cx/compare/hexarelin-vs-ghrp-2) ## Goal hubs - [Peptides Researched for Muscle Growth & Performance](https://peptides.cx/library/for/muscle-growth) - [Peptides Researched for Recovery & Healing](https://peptides.cx/library/for/recovery-healing) - [Peptides Researched for Longevity & Anti-Aging](https://peptides.cx/library/for/longevity-antiaging) - [Peptides Researched for Fat Loss & Metabolic Health](https://peptides.cx/library/for/fat-loss-metabolic) - [Peptides Researched for Skin, Hair & Beauty](https://peptides.cx/library/for/skin-hair-beauty) - [Peptides Researched for Sleep & Stress](https://peptides.cx/library/for/sleep-stress) - [Peptides Researched for Cognition & Focus](https://peptides.cx/library/for/cognitive-focus) - [Peptides Researched for Gut & Immune Health](https://peptides.cx/library/for/gut-immune) - [Peptides Researched for Sexual & Hormonal Health](https://peptides.cx/library/for/sexual-hormonal) ## Knowledge base - [What Are Peptides? A Complete Beginner's Guide](https://peptides.cx/learn/what-are-peptides) - [Peptides vs Proteins: What's the Difference?](https://peptides.cx/learn/peptides-vs-proteins) - [Peptides vs Hormones: How They Relate](https://peptides.cx/learn/peptides-vs-hormones) - [How Do Peptides Work? Mechanisms Explained](https://peptides.cx/learn/how-peptides-work) - [How Peptides Are Made: Synthesis & Quality](https://peptides.cx/learn/how-peptides-are-made) - [Peptide Half-Life, Stability & Delivery Explained](https://peptides.cx/learn/peptide-half-life-and-delivery) - [Understanding Peptide Evidence: From Anecdote to Clinical Trial](https://peptides.cx/learn/understanding-peptide-evidence) - [Peptide Safety, Side Effects & Contamination Risks](https://peptides.cx/learn/peptide-safety-and-risks) - [What 'Research Peptides' Really Means](https://peptides.cx/learn/research-peptides-explained) - [How to Read a Peptide Certificate of Analysis (COA)](https://peptides.cx/learn/how-to-read-a-coa) - [Peptide Legality & Regulation: EU, US & Beyond](https://peptides.cx/learn/peptide-regulation-eu-us) - [Peptide Glossary: Key Terms Explained](https://peptides.cx/learn/peptide-glossary) ## Complete corpus Fetch https://peptides.cx/llms-full.txt for full monograph text and source lists.